Artwork

Innhold levert av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Real-World Nursing Solutions for AML Care: Insights on the Effective and Safe Delivery of Innovative Therapeutics

16:11
 
Del
 

Manage episode 361945281 series 103590
Innhold levert av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Go online to PeerView.com/GFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oncology nurse professionals play a particularly important role in providing high-quality and increasingly personalized care to patients with acute myeloid leukemia (AML)—but how current are you with the “real-world” practice of nursing care in AML? Find out in this activity, featuring an oncology nurse’s expert overview of nursing principles that can be used to modernize care and optimize the use of innovative targeted therapies (such as FLT3, IDH1/2, and BCL-2 inhibitors) across the treatment continuum. Upon completion of this activity, participants should be better able to: Recognize clinical symptoms, patient-related factors, and molecular/genetic features that influence AML treatment decisions and prognosis; Summarize efficacy and safety evidence related to novel targeted and epigenetic options for the management of newly diagnosed AML, postremission disease, and the relapsed/refractory setting; Educate patients with AML about therapeutic choices with novel agent classes, treatment expectations, dosing and adherence, and safety considerations; and Manage adverse events experienced by patients with AML receiving novel targeted and epigenetic options as part of their care.
  continue reading

370 episoder

Artwork
iconDel
 
Manage episode 361945281 series 103590
Innhold levert av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Go online to PeerView.com/GFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oncology nurse professionals play a particularly important role in providing high-quality and increasingly personalized care to patients with acute myeloid leukemia (AML)—but how current are you with the “real-world” practice of nursing care in AML? Find out in this activity, featuring an oncology nurse’s expert overview of nursing principles that can be used to modernize care and optimize the use of innovative targeted therapies (such as FLT3, IDH1/2, and BCL-2 inhibitors) across the treatment continuum. Upon completion of this activity, participants should be better able to: Recognize clinical symptoms, patient-related factors, and molecular/genetic features that influence AML treatment decisions and prognosis; Summarize efficacy and safety evidence related to novel targeted and epigenetic options for the management of newly diagnosed AML, postremission disease, and the relapsed/refractory setting; Educate patients with AML about therapeutic choices with novel agent classes, treatment expectations, dosing and adherence, and safety considerations; and Manage adverse events experienced by patients with AML receiving novel targeted and epigenetic options as part of their care.
  continue reading

370 episoder

Alla avsnitt

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett